Marketwatch: Implications of expanding disease definitions: The case of osteoporosis

Health Affairs

Volumn 26, Issue 6, 2007, Pages 1702-1711

  Herndon, M Brooke ^a   Schwartz, Lisa M ^a,b   Woloshin, Steven ^a,b   Welch, H Gilbert ^a,b  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b VA Outcomes Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGE; AGED; ARTICLE; ECONOMICS; FEMALE; FORECASTING; HEALTH CARE COST; HIP FRACTURE; HUMAN; MEDICAL SOCIETY; MIDDLE AGED; NEEDS ASSESSMENT; POSTMENOPAUSE OSTEOPOROSIS; RISK FACTOR;

AGE FACTORS; AGED; FEMALE; FORECASTING; HEALTH CARE COSTS; HIP FRACTURES; HUMANS; MIDDLE AGED; NEEDS ASSESSMENT; OSTEOPOROSIS, POSTMENOPAUSAL; RISK FACTORS; SOCIETIES, MEDICAL;

EID: 36849062108     PISSN: 02782715     EISSN: 02782715     Source Type: Journal    
DOI: 10.1377/hlthaff.26.6.1702     Document Type: Article

References (40)

1. L.M. Schwartz and S. Woloshin, "Changing Disease Definitions: Implications for Disease Prevalence: Analysis of the Third National Health and Nutrition Examination Survey, 1988-1994," Effective Clinical Practice 2, no. 2 (1999): 76-85;
2. R. Moynihan, I. Heath, and D. Henry, "Selling Sickness: The Pharmaceutical Industry and Disease Mongering," British Medical Journal 324, no. 7342 (2002): 886-891;
3. and R. Moynihan and A. Cassels, Selling Sickness: How the World's Biggest Pharmaceutical Companies Are Turning Us All into Patients (New York: Nation Books, 2005).
4. F. Leynen et al., "Increased Absenteeism from Work among Aware and Treated Hypertensive and Hypercholesterolaemic Patients," European Journal of Cardiovascular Prevention and Rehabilitation 13, no. 2 (2006): 261-267.
5. If a woman has a T-score of zero, it means that her bonemineral density is the same as themean for young white women. A negative T-score means that her bones are less dense than that mean. The more negative her T-score, the less dense her bones; for example, a T-score of -2.5 is worse than a T-score of -1.5.
6. National Osteoporosis Foundation, Physician's Guide to Prevention and Treatment of Osteoporosis (Washington: NOF, 2003), 7-22.
7. K.L. Stone et al., "BMD at Multiple Sites and Risk of Fracture of Multiple Types: Long-Term Results from the Study of Osteoporotic Fractures," Journal of Bone and Mineral Research 18, no. 11 (2003): 1947-1954;
8. A.M. Schott et al., "How Hip and Whole-Body Bone Mineral Density Predict Hip Fracture in Elderly Women: The EPIDOS Prospective Study," Osteoporosis International 8, no. 3 (1998): 247-254;
9. and E.S. Siris et al., "Bone Mineral Density Thresholds for Pharmacological Intervention to Prevent Fractures," Archives of Internal Medicine 164, no. 10 (2004): 1108-1112.
10. National Center for Health Statistics, Plan and Operation of the Third National Health and Nutrition Examination Survey, 1988-94, Vital and Health Statistics Series 1, no. 32, Pub. no. (PHS)94-1308, July 1994, http://www.cdc.gov/nchs/data/series/sr_01/sr01_032.pdf (accessed 25 September 2007);
11. and U.S. Department of Health and Human Services and NCHS, "Third National Health and Nutrition Examination Survey, 1988-1994, NHANES III Household Adult and Laboratory Data Files (CD-ROM)," Public Use Data File Documentation no. 76200 (Hyattsville, Md.: NCHS, 1996).
12. J.A. Kanis, "Diagnosis of Osteoporosis and Assessment of Fracture Risk," Lancet 359, no. 9321 (2002): 1929-1936;
13. S.R. Cummings et al., "Bone Density at Various Sites for Prediction of Hip Fractures: The Study of Osteoporotic Fractures Research Group," Lancet 341, no. 8837 (1993): 72-75;
14. and H.D. Nelson et al., "Screening for Postmenopausal Osteoporosis: A Review of the Evidence for the U.S. Preventive Services Task Force," Annals of Internal Medicine 137, no. 6 (2002): 529-541.
15. Twenty-two women were considered not eligible for scanning because they had either a pregnancy test that was not clearly negative, a history of bilateral hip fracture, or hip surgery involving placement of orthopedic hardware.
16. For details of the NHANES sample selection, see White River Junction VA Outcomes Group, "Hip Fracture Life Table," http://www.vaoutcomes.org/ downloads/hip_fracture_life_table.xls (accessed 25 September 2007).
17. A.C. Looker et al., "Prevalence of Low Femoral Bone Density in Older U.S. Adults from NHANES III," Journal of Bone and Mineral Research 12, no. 11 (1997): 1761-1768.
18. Kanis, "Diagnosis of Osteoporosis"; and Cummings et al., "Bone Density at Various Sites."
19. "ACOG Practice Bulletin: Clinical Management Guidelines for Obstetrician-Gynecologists, Number 50," Obstetrics and Gynecology 103, no. 1 (2004): 203-216.
20. Healthcare Cost and Utilization Project, "Introduction to the HCUP Nationwide Inpatient Sample (NIS), 2002," p. 22, June 2004, http://www.hcup-us.ahrq.gov/db/nation/nis/Introduction_to_NIS_2002.pdf (accessed 7 August 2007);
21. and HCUP, "Design of the HCUP Nationwide Inpatient Sample, 2000," p. 17, 24 May 2002, http://www.hcup-us.ahrq.gov/db/nation/nis/ reports/NIS_2000_Design_Report.pdf (accessed 7 August 2007).
22. For the complete life table, see Note 9.
23. S.R. Cummings, D. Bates, and D.M. Black, "Clinical Use of Bone Densitometry: Scientific Review," Journal of the American Medical Association 288, no. 15 (2002): 1889-1897. Details of all calculations are provided in an online appendix, available at http://content.healthaffairs.org/ cgi/content/full/26/6/1702/DC1.
24. J.T. Schousboe et al., "Cost-Effectiveness of Alendronate Therapy for Osteopenic Postmenopausal Women," Annals of Internal Medicine 142, no. 9 (2005): 734-741.
25. A. Cranney et al., "Meta-Analyses of Therapies for Postmenopausal Osteoporosis, IX: Summary of Meta-Analyses of Therapies for Postmenopausal Osteoporosis," Endocrine Reviews 23, no. 4 (2002): 570-578.
26. U.A. Liberman et al., "Effect of Oral Alendronate on Bone Mineral Density and the Incidence of Fractures in Postmenopausal Osteoporosis: The Alendronate Phase III Osteoporosis Treatment Study Group," New England Journal of Medicine 333, no. 22 (1995): 1437-1443;
27. M.R. McClung et al., "Effect of Risedronate on the Risk of Hip Fracture in Elderly Women: Hip Intervention Program Study Group," New England Journal of Medicine 344, no. 5 (2001): 333-340.
28. D.M. Black et al., "Randomised Trial of Effect of Alendronate on Risk of Fracture in Women with Existing Vertebral Fractures: Fracture Intervention Trial Research Group," Lancet 348, no. 9041 (1996): 1535-1541.
29. S.R. Cummings et al., "Effect of Alendronate on Risk of Fracture in Women with Low Bone Density but without Vertebral Fractures: Results from the Fracture Intervention Trial," Journal of the American Medical Association 280, no. 24 (1998): 2077-2082.
30. S.B. Jaglal et al., "Patterns of Use of the Bone Mineral Density Test in Ontario, 1992-1998," Canadian Medical Association Journal 163, no. 9 (2000): 1139-1143.
31. S.B. Woo, J.W. Hellstein, and J.R. Kalmar, "Narrative [Corrected] Review: Bisphosphonates and Osteonecrosis of the Jaws," Annals of Internal Medicine 144, no. 10 (2006): 753-761.
32. J.A. Kanis et al., "Ten Year Probabilities of Osteoporotic Fractures According to BMD and Diagnostic Thresholds," Osteoporosis International 12, no. 12 (2001): 989-995.
33. J.A. Cauley et al., "Risk of Mortality Following Clinical Fractures," Osteoporosis International 11, no. 7 (2000): 556-561;
34. C.L. Leibson et al., "Mortality, Disability, and Nursing Home Use for Persons With and Without Hip Fracture: A Population-Based Study," Journal of the American Geriatrics Society 50, no. 10(2002): 1644-1650;
35. and J. Richmond et al., "Mortality Risk after Hip Fracture," Journal of Orthopedic Trauma 17, no. 8 Supp. (2003): S2-S5.
36. D. Marshall, O. Johnell, and H. Wedel, "Meta-Analysis of How Well Measures of Bone Mineral Density Predict Occurrence of Osteoporotic Fractures," British Medical Journal 312, no. 7041 (1996): 1254-1259;
37. and S.A. Wainwright et al., "A Large Proportion of Fractures in Postmenopausal Women Occur with Baseline Bone Mineral Density T-Score -2.5" (Paper presented at the American Society for Bone and Mineral Research, Phoenix, Arizona, October 2001).
38. J.A. Kanis, "Assessment of Fracture Risk and Its Application to Screening for Postmenopausal Osteoprosis: Synopsis of a WHO Report," Osteoporosis International 4, no. 6 (1994): 368-381.
39. National Osteoporosis Foundation, Building on Our Strong Foundation: 2005 Annual Report, http://www.nof.org/aboutnof/2005_Annual_Report_FINAL.pdf (accessed 7 August 2007);
40. and American College of Obstetrics-Gynecology, "Friends of ACOG," http://www.acog.org/departments/dept_notice.cfm?recno= 41&bulletin=3083 (accessed 7 August 2007).